Logo image of CNST

Constellation Pharmaceuticals Inc (CNST) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CNST -

33.99
+0.02 (+0.06%)
Last: 7/14/2021, 8:14:04 PM
33.99
0 (0%)
After Hours: 7/14/2021, 8:14:04 PM
Fundamental Rating

2

Taking everything into account, CNST scores 2 out of 10 in our fundamental rating. CNST was compared to 530 industry peers in the Biotechnology industry. CNST scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. CNST does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CNST had negative earnings in the past year.

1.2 Ratios

Industry RankSector Rank
ROA -35.01%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CNST so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

6

2. Health

2.1 Basic Checks

There is no outstanding debt for CNST. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

An Altman-Z score of 36.79 indicates that CNST is not in any danger for bankruptcy at the moment.
CNST has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 36.79
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 15.39 indicates that CNST has no problem at all paying its short term obligations.
A Quick Ratio of 15.39 indicates that CNST has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 15.39
Quick Ratio 15.39

More info and screens

0

3. Growth

3.1 Past

The earnings per share for CNST have decreased by -4.11% in the last year.
EPS 1Y (TTM)-4.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-37.7%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, CNST will show a decrease in Earnings Per Share. The EPS will decrease by -5.41% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-28.75%
EPS Next 2Y-18.15%
EPS Next 3Y-11.2%
EPS Next 5Y-5.41%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CNST Yearly Revenue VS EstimatesCNST Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 50M 100M 150M
CNST Yearly EPS VS EstimatesCNST Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CNST. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CNST. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CNST Price Earnings VS Forward Price EarningsCNST Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -9.03
CNST Per share dataCNST EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

A cheap valuation may be justified as CNST's earnings are expected to decrease with -11.20% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-18.15%
EPS Next 3Y-11.2%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CNST!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Constellation Pharmaceuticals Inc

NASDAQ:CNST (7/14/2021, 8:14:04 PM)

After market: 33.99 0 (0%)

33.99

+0.02 (+0.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)03-04 2022-03-04/bmo
Inst Owners0.37%
Inst Owner Change0%
Ins Owners24.99%
Ins Owner Change0%
Market Cap1.63B
Revenue(TTM)N/A
Net Income(TTM)-140.99M
Analysts71.4
Price Target41.53 (22.18%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.32
P/tB N/A
EV/EBITDA -9.03
EPS(TTM)-3.04
EYN/A
EPS(NY)-3.92
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS7.87
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -35.01%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.39
Quick Ratio 15.39
Altman-Z 36.79
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-4.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-37.7%
EPS Next Y-28.75%
EPS Next 2Y-18.15%
EPS Next 3Y-11.2%
EPS Next 5Y-5.41%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

Constellation Pharmaceuticals Inc / CNST FAQ

Can you provide the ChartMill fundamental rating for Constellation Pharmaceuticals Inc?

ChartMill assigns a fundamental rating of 2 / 10 to CNST.


Can you provide the valuation status for Constellation Pharmaceuticals Inc?

ChartMill assigns a valuation rating of 1 / 10 to Constellation Pharmaceuticals Inc (CNST). This can be considered as Overvalued.


What is the profitability of CNST stock?

Constellation Pharmaceuticals Inc (CNST) has a profitability rating of 1 / 10.


What is the earnings growth outlook for Constellation Pharmaceuticals Inc?

The Earnings per Share (EPS) of Constellation Pharmaceuticals Inc (CNST) is expected to decline by -28.75% in the next year.